These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10650806)

  • 1. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial.
    Gridelli C; Perrone F; Gallo C; Rossi A; Barletta E; Barzelloni ML; Creazzola S; Gatani T; Fiore F; Guida C; Scognamiglio F
    Anticancer Res; 1999; 19(5C):4535-8. PubMed ID: 10650806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
    Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
    Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer.
    van Putten JW; Baas P; Codrington H; Kwa HB; Muller M; Aaronson N; Groen HJ
    Lung Cancer; 2001; 33(2-3):289-98. PubMed ID: 11551424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
    Anderson H; Hopwood P; Stephens RJ; Thatcher N; Cottier B; Nicholson M; Milroy R; Maughan TS; Falk SJ; Bond MG; Burt PA; Connolly CK; McIllmurray MB; Carmichael J
    Br J Cancer; 2000 Aug; 83(4):447-53. PubMed ID: 10945489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
    J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
    Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
    Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
    Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
    Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
    Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
    Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
    Gillenwater HH; Stinchcombe TE; Qaqish BF; Tyann M; Hensing TA; Socinski MA
    Lung Cancer; 2005 Mar; 47(3):413-9. PubMed ID: 15713525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.
    Crinò L; Mosconi AM; Scagliotti G; Selvaggi G; Novello S; Rinaldi M; Della Giulia M; Gridelli C; Rossi A; Calandri C; De Marinis F; Noseda M; Tonato M
    J Clin Oncol; 1999 Jul; 17(7):2081-5. PubMed ID: 10561261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.
    Quoix E; Breton JL; Ducoloné A; Mennecier B; Depierre A; Lemarié E; Moro-Sibilot D; Germa C; Neidhardt AC
    Lung Cancer; 2005 Mar; 47(3):405-12. PubMed ID: 15713524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
    Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
    Ferrigno D; Buccheri G;
    Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.
    Gridelli C; De Maio E; Barbera S; Sannicolo M; Piazza E; Piantedosi F; Brancaccio L; Morabito A; Maione P; Renda F; Signoriello G; Perrone F;
    Lung Cancer; 2008 Jul; 61(1):67-72. PubMed ID: 18683299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
    Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
    Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.